Prof. Alberto Danielli will showcase pioneering research on the application of bacteriophage biotechnology in oncology, bridging the gap between fundamental science and clinical applications. His talk will explore how engineered phages can revolutionize cancer therapy through drug delivery, tumor targeting, and immunomodulation.
Key Topics:
- Engineering bacteriophages to selectively bind tumor-specific antigens
- Utilizing phage-derived vectors for targeted drug transport in solid tumors and across biological barriers
- Investigating the oncolytic and immunomodulatory potential of engineered phages
- Evaluating preclinical safety and efficacy.
Sigificant & Impact :
This presentation will illustrate how phage biotechnology can contribute to cancer treatment, offering targeted therapies with minimized side effects. Prof. Danielli will also discuss future directions in integrating synthetic biology, nanotechnology, and immunotherapy into phage-based platforms, opening new frontiers in precision oncology.
Targeting Phage Therapy 2025
June 10-11, 2025 – Berlin, Germany
